Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.02 
Primary Endpoint Analysis: CIBIC+ - Summary at Week 24 - LOCF 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=79)  
Xanomeline 
 Low Dose 
 (N=81)  
Xanomeline 
 High Dose 
 (N=74)  
Week 24 
  n                                   79 
  81 
  74 
  Mean (SD)                            4.3 (0.77) 
   4.2 (0.79) 
   4.3 (0.81) 
  Median (Range)                       4.0 (2;6) 
   4.0 (2;6) 
   4.0 (3;6) 
 
  p-value(Dose Response) [1][2]      
 
  0.960 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.489 
   0.799 
   Diff of LS Means (SE)            
 
-0.1 (0.13) 
0.0 (0.13) 
   95% CI                           
 
(-0.3;0.2) 
(-0.2;0.3) 
 
  p-value(Xan High - Xan Low)[1][3]  
 
 
   0.349 
   Diff of LS Means (SE)            
 
 
0.1 (0.13) 
   95% CI                           
 
 
(-0.1;0.4) 
 
